Why Avenue Therapeutics (ATXI) Stock Is Falling Sharply

Avenue Therapeutics ATXI shares are trading lower by 20.7% to $4.92 during Monday’s session after the company announced the exercise of warrants for $4.4 million in gross proceeds.

These warrants were issued at different times with various exercise prices, but the warrant holders have agreed to exercise them at a reduced price of $6.20 per share. The company expects to receive approximately $4.4 million in gross proceeds from this exercise.

In return for exercising the warrants, Avenue will issue new unregistered Series C and Series D warrants to the warrant holders, each allowing them to purchase up to 689,680 shares of common stock at an exercise price of $6.20 per share.

The new Series C warrants will be exercisable immediately and valid for five years, while the Series D warrants will be exercisable immediately but valid for eighteen months. The transaction is expected to close around May 1, 2024, subject to standard closing conditions.

See Also: Broadcom, Marvell Set To Capitalize On AI Investments From Microsoft, Alphabet, Meta: JPMorgan

Should I Sell My ATXI Stock?

When deciding to hold on to or sell a stock, investors should consider their time horizon, unrealized gains and total return.

Shares of Avenue Therapeutics have decreased by 93.29% in the past year. An investor who bought shares of Avenue Therapeutics at the beginning of the year would take a loss of $7.05 per share if they sold it today. The stock has fallen 56.03% over the past month, meaning an investor who bought shares on Mar. 1 would see a capital loss of $6.95.

Investors may also consider market dynamics. The Relative Strength Index can be used to indicate whether a stock is overbought or oversold. Avenue Therapeutics stock currently has an RSI of 27.91, indicating oversold conditions.

For access to advanced charting and analysis tools and stock data, check out Benzinga PRO. Try it for free.

ATXI has a 52-week high of $93.75 and a 52-week low of $4.77.